These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37935033)

  • 21. Beneficial metabolic effects of recurrent periods of beta-cell rest and stimulation using stable neuropeptide Y1 and glucagon-like peptide-1 receptor agonists.
    Tanday N; Lafferty RA; Flatt PR; Irwin N
    Diabetes Obes Metab; 2022 Dec; 24(12):2353-2363. PubMed ID: 35848461
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel anti-obesity mechanism for liraglutide by improving adipose tissue leptin resistance in high-fat diet-fed obese mice.
    Lyu X; Yan K; Wang X; Xu H; Guo X; Zhu H; Pan H; Wang L; Yang H; Gong F
    Endocr J; 2022 Oct; 69(10):1233-1244. PubMed ID: 35705299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models.
    Killion EA; Wang J; Yie J; Shi SD; Bates D; Min X; Komorowski R; Hager T; Deng L; Atangan L; Lu SC; Kurzeja RJM; Sivits G; Lin J; Chen Q; Wang Z; Thibault SA; Abbott CM; Meng T; Clavette B; Murawsky CM; Foltz IN; Rottman JB; Hale C; Véniant MM; Lloyd DJ
    Sci Transl Med; 2018 Dec; 10(472):. PubMed ID: 30567927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liraglutide and Exercise Synergistically Attenuate Vascular Inflammation and Enhance Metabolic Insulin Action in Early Diet-Induced Obesity.
    Liu J; Aylor KW; Liu Z
    Diabetes; 2023 Jul; 72(7):918-931. PubMed ID: 37074396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.
    Henderson SJ; Konkar A; Hornigold DC; Trevaskis JL; Jackson R; Fritsch Fredin M; Jansson-Löfmark R; Naylor J; Rossi A; Bednarek MA; Bhagroo N; Salari H; Will S; Oldham S; Hansen G; Feigh M; Klein T; Grimsby J; Maguire S; Jermutus L; Rondinone CM; Coghlan MP
    Diabetes Obes Metab; 2016 Dec; 18(12):1176-1190. PubMed ID: 27377054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Partial leptin deficiency confers resistance to diet-induced obesity in mice.
    Zhao S; Li N; Zhu Y; Straub L; Zhang Z; Wang MY; Zhu Q; Kusminski CM; Elmquist JK; Scherer PE
    Mol Metab; 2020 Jul; 37():100995. PubMed ID: 32289482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elimination of glucagon-like peptide 1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action.
    Scrocchi LA; Hill ME; Saleh J; Perkins B; Drucker DJ
    Diabetes; 2000 Sep; 49(9):1552-60. PubMed ID: 10969840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacologic stimulation of central GLP-1 receptors has opposite effects on the alterations of plasma FGF21 levels induced by feeding and fasting.
    Nonogaki K; Kaji T; Yamazaki T; Murakami M
    Neurosci Lett; 2016 Jan; 612():14-17. PubMed ID: 26683903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dietary Cyanidin-3-Glucoside Attenuates High-Fat-Diet-Induced Body-Weight Gain and Impairment of Glucose Tolerance in Mice via Effects on the Hepatic Hormone FGF21.
    Tian L; Ning H; Shao W; Song Z; Badakhshi Y; Ling W; Yang BB; Brubaker PL; Jin T
    J Nutr; 2020 Aug; 150(8):2101-2111. PubMed ID: 32470979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Obesity medication lorcaserin activates brainstem GLP-1 neurons to reduce food intake and augments GLP-1 receptor agonist induced appetite suppression.
    Wagner S; Brierley DI; Leeson-Payne A; Jiang W; Chianese R; Lam BYH; Dowsett GKC; Cristiano C; Lyons D; Reimann F; Gribble FM; Martinez de Morentin PB; Yeo GSH; Trapp S; Heisler LK
    Mol Metab; 2023 Feb; 68():101665. PubMed ID: 36592795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
    Secher A; Jelsing J; Baquero AF; Hecksher-Sørensen J; Cowley MA; Dalbøge LS; Hansen G; Grove KL; Pyke C; Raun K; Schäffer L; Tang-Christensen M; Verma S; Witgen BM; Vrang N; Bjerre Knudsen L
    J Clin Invest; 2014 Oct; 124(10):4473-88. PubMed ID: 25202980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GLP-1 receptor agonist improves metabolic disease in a pre-clinical model of lipodystrophy.
    Roumane A; Mcilroy GD; Sommer N; Han W; Heisler LK; Rochford JJ
    Front Endocrinol (Lausanne); 2024; 15():1379228. PubMed ID: 38745956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet.
    Somm E; Montandon SA; Loizides-Mangold U; Gaïa N; Lazarevic V; De Vito C; Perroud E; Bochaton-Piallat ML; Dibner C; Schrenzel J; Jornayvaz FR
    Transl Res; 2021 Jan; 227():75-88. PubMed ID: 32711187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of the glucagon-like peptide-1 analogue liraglutide versus placebo treatment on circulating proglucagon-derived peptides that mediate improvements in body weight, insulin secretion and action: A randomized controlled trial.
    Kim SH; Abbasi F; Nachmanoff C; Stefanakis K; Kumar A; Kalra B; Savjani G; Mantzoros CS
    Diabetes Obes Metab; 2021 Feb; 23(2):489-498. PubMed ID: 33140542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peptide-YY
    Boland BB; Laker RC; O'Brien S; Sitaula S; Sermadiras I; Nielsen JC; Barkholt P; Roostalu U; Hecksher-Sørensen J; Sejthen SR; Thorbek DD; Suckow A; Burmeister N; Oldham S; Will S; Howard VG; Gill BM; Newton P; Naylor J; Hornigold DC; Austin J; Lantier L; McGuinness OP; Trevaskis JL; Grimsby JS; Rhodes CJ
    Mol Metab; 2022 Jan; 55():101392. PubMed ID: 34781035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists.
    Ard J; Fitch A; Fruh S; Herman L
    Adv Ther; 2021 Jun; 38(6):2821-2839. PubMed ID: 33977495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liraglutide Modulates Appetite and Body Weight Through Glucagon-Like Peptide 1 Receptor-Expressing Glutamatergic Neurons.
    Adams JM; Pei H; Sandoval DA; Seeley RJ; Chang RB; Liberles SD; Olson DP
    Diabetes; 2018 Aug; 67(8):1538-1548. PubMed ID: 29776968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
    Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
    Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.
    Monfeuga T; Norlin J; Bugge A; Gaalsgaard ED; Prada-Medina CA; Latta M; Veidal SS; Petersen PS; Feigh M; Holst D
    Mol Metab; 2024 Jan; 79():101850. PubMed ID: 38065435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Time and metabolic state-dependent effects of GLP-1R agonists on NPY/AgRP and POMC neuronal activity in vivo.
    Dong Y; Carty J; Goldstein N; He Z; Hwang E; Chau D; Wallace B; Kabahizi A; Lieu L; Peng Y; Gao Y; Hu L; Betley JN; Williams KW
    Mol Metab; 2021 Dec; 54():101352. PubMed ID: 34626854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.